Showing results (41-50 of 128) with videos related to
Sort By:
Pageof 13
Journal of Radiation Research|August 12, 2004
In vivo radioprotection of mice by 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone; Radicut), a clinical drugKazunori Anzai, Masako Furuse, Akira Yoshida, et al.Japanese Journal of Cancer Research : Gann|April 3, 2002
Selective expansion of human natural killer cells from peripheral blood mononuclear cells by the cell line, HFWTHideki Harada, Kaoru Saijo, Satoru Watanabe, et al.Neurologia Medico-Chirurgica|December 11, 2002
Chondroblastoma of the temporal base with high mitotic activityEiichi Ishikawa, Koji Tsuboi, Kojiro Onizawa, et al.Technical Innovations & Patient Support in Radiation Oncology|February 1, 2024
Single isocenter dynamic conformal arcs-based radiosurgery for brain metastases: Dosimetric comparison with Cyberknife and clinical investigationYoshiko Oshiro, Masashi Mizumoto, Yuichi Kato, et al.Cancer Science|May 23, 2007
Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patientsEiichi Ishikawa, Koji Tsuboi, Tetsuya Yamamoto, et al.Neurologia Medico-Chirurgica|September 1, 2010
Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatmentEiichi Ishikawa, Tetsuya Yamamoto, Noriaki Sakamoto, et al.Radiation Research|July 25, 2018
Antimetastatic Effects of Carbon-Ion Beams on Malignant MelanomasYoshitaka Matsumoto, Yoshiya Furusawa, Akiko Uzawa, et al.Journal of Radiation Research|April 15, 2021
Long-term outcomes of patients with unresectable benign meningioma treated with proton beam therapyHiroshige Sato, Masashi Mizumoto, Toshiyuki Okumura, et al.Scientific Reports|July 1, 2016
Methylmercury, an environmental electrophile capable of activation and disruption of the Akt/CREB/Bcl-2 signal transduction pathway in SH-SY5Y cellsTakamitsu Unoki, Yumi Abiko, Takashi Toyama, et al.International Journal of Radiation Oncology, Biology, Physics|October 5, 2010
Proton beam therapy of Stage II and III non-small-cell lung cancerHidetsugu Nakayama, Hiroaki Satoh, Shinji Sugahara, et al.Pageof 13